# Quest Diagnostics (DGX) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/DGX
## Company Profile
- Ticker: DGX
- Exchange: NYSE
- Sector: Diagnostics and Healthcare Services
- Location: United States
- Tags: Biopharma, Diagnostics, Life Science Tools
## Stock Data
- Close: 210.68 USD
- Market cap: 22962867231.76 USD
- Last updated: 2026-07-17
## Business Overview
Quest Diagnostics is a diagnostics and life sciences tools company focused on testing, assay adoption, and workflow utility, with investors watching recurring demand and product mix as much as clinical news flow.
## Why The Stock Is Moving

DGX is trading more like a diagnostics and healthcare services name than a classic biotech binary. Investors tend to focus on testing volume, reimbursement, and operating leverage, so the stock usually responds to utilization trends and earnings cadence rather than one-off clinical catalysts.

## Geographic Base

Headquartered in the United States and listed on NYSE, Quest Diagnostics is followed within the diagnostics and tools universe for its exposure to customer demand and adoption cycles.

## Business Model

Quest Diagnostics is a commercial-tools story where install base, recurring demand, and product adoption drive the narrative more than one-off clinical events.

## Landscape Position

Compared with therapeutic biotech names, Quest Diagnostics sits on a different part of the landscape where utilization, customer demand, and product refresh tend to matter more than binary FDA events.

## Future Catalysts

- Over the next three months, the most important checkpoints are earnings, reimbursement commentary, and any update on testing demand or specialty diagnostics mix.
- Investors also watch acquisition activity, health-plan access, and workflow adoption because they can shift the margin profile without relying on a single trial event.
- Conference appearances and peer commentary may matter, but the stock usually moves more on utilization and pricing detail than on binary FDA headlines.
- Advanced diagnostics adoption remains the longer-term upside lever, especially where precision medicine and companion testing expand the addressable market.

## Recent News
- 2026-07-20 10:59 EST — [Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA](https://biopharmsignal.com/news/BMY/bristol-myers-squibb-to-build-the-most-powerful-ai-factory-in-life-sciences-with-eb3e7bda) — Source: BMYBristol-Myers Squibb Company
- 2026-07-20 07:00 EST — [European Medicines Agency accepts submission to update Bexsero label for 1-dose Meningitis B booster in 10+ year olds](https://biopharmsignal.com/news/GSK/european-medicines-agency-accepts-submission-to-update-bexsero-label-for-1-dose--8906d096) — Source: GSK plc
- 2026-07-17 09:00 EST — [GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)](https://biopharmsignal.com/news/GSK/gsk-provides-an-update-on-calm-1-and-calm-2-phase-iii-trials-for-camlipixant-in--0e112206) — Source: GSK plc
- 2026-07-16 12:31 EST — [Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia](https://biopharmsignal.com/news/MRK/merck-s-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibit-1b899588) — Source: Merck
- 2026-07-16 12:00 EST — [Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALNY/alnylam-to-webcast-conference-call-discussing-second-quarter-2026-financial-resu-458d7635) — Source: Alnylam Pharmaceuticals, Inc.